Status:
COMPLETED
Galantamine Effects on Cognitive Function in Abstinent Cocaine Users
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Cocaine Abuse
Eligibility:
All Genders
21-50 years
Phase:
NA
Brief Summary
To evaluate galantamine's effects on cognitive performance in abstinent cocaine users. Galantamine, a medication approved for treatment of Alzheimer's disease, is an acetylcholine esterase inhibitor. ...
Detailed Description
Galantamine, compared to placebo, will improve cognitive performance in abstinent cocaine users. The cognitive performance will be measured with the Stroop test and 3 Cambridge Neuropsychological Test...
Eligibility Criteria
Inclusion
- Male and females, between the ages 21 and 50
- Fulfill criteria for past cocaine dependence
- No cocaine use for the past 30 days
- No other current dependence or abuse of other drugs or alcohol
- No current medical problems and normal ECG
- Not pregnant,nor breast feeding,
- Using acceptable birth control methods.
Exclusion
- Current major psychiatric illness including mood, psychotic or anxiety disorders
- History of major medical illnesses; including asthma or chronic obstructive lung disease, history or current gastrointestinal ulcer, hepatic or renal impairment and cardiac rhythm disturbances
- Use of other medications including,drugs that slow heart rate
- Known allergy to galantamine
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00606801
Start Date
June 1 2007
End Date
February 1 2009
Last Update
March 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Veterans Affairs Hospital
West Haven, Connecticut, United States, 06516